Adjuvant Immunotherapy After Neoadjuvant Treatment for Esophageal Cancer
Author Information
Author(s): Feng Jifeng, Wang Liang, Yang Xun, Chen Qixun
Primary Institution: Zhejiang Cancer Hospital
Hypothesis
Does adjuvant immunotherapy improve outcomes for patients with esophageal squamous cell carcinoma after neoadjuvant immunochemotherapy and surgery?
Conclusion
Adjuvant immunotherapy improves disease-free and overall survival in patients with ypT+N+ esophageal squamous cell carcinoma after neoadjuvant treatment and surgery.
Supporting Evidence
- Adjuvant immunotherapy significantly improved disease-free survival in patients with ypT+N+ esophageal squamous cell carcinoma.
- Patients receiving adjuvant immunotherapy had a lower risk of recurrence compared to those who did not.
- The study included a diverse cohort of patients treated with various immunotherapy agents.
Takeaway
This study found that giving extra treatment after surgery helps some patients with a specific type of esophageal cancer live longer and stay healthier.
Methodology
A retrospective analysis of patients who underwent neoadjuvant immunochemotherapy and surgery for esophageal squamous cell carcinoma, comparing disease-free survival and overall survival using Kaplan-Meier curves and Cox models.
Potential Biases
The selection of patients for adjuvant immunotherapy may introduce bias, as it was based on clinician judgment rather than random assignment.
Limitations
This is a retrospective study from a single institution, and the decision for patients to receive adjuvant immunotherapy was selectively determined by clinicians.
Participant Demographics
The study included 215 patients with a mean age of 63.3 years, consisting of 190 men (88.4%) and 25 women (11.6%).
Statistical Information
P-Value
P=0.036 for DFS in ypT+N+; P=0.010 for OS in ypT+N+
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website